Curasight resumes enrolment in Phase 1 glioblastoma uTREAT study after protocol amendment approval
Bitget2026/10/05 06:42Curasight resumed patient enrollment in its Phase 1 glioblastoma study following clearance of a protocol amendment. The revised trial design drops mannitol-induced blood-brain barrier disruption for newly enrolled patients receiving uTREAT. No clinical results have been presented yet; topline Phase 1 data are expected in H1 2027. The change aims to support a more robust dataset to guide later dose-finding and Phase 2 development decisions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curasight A/S published the original content used to generate this news brief via Cision (Ref. ID: 20261005:BIT:8912:0) on October 05, 2026, and is solely responsible for the information contained therein.
- Curasight resumed patient enrollment in its Phase 1 glioblastoma study following clearance of a protocol amendment.
- The revised trial design drops mannitol-induced blood-brain barrier disruption for newly enrolled patients receiving uTREAT.
- No clinical results have been presented yet; topline Phase 1 data are expected in H1 2027.
- The change aims to support a more robust dataset to guide later dose-finding and Phase 2 development decisions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ – US Stock Market Updates: Nvidia, Genmab, Eli Lilly
British Pound hits session highs at 1.3420 amid broadbased US Dollar weakness
Crypto prices
More
